ABSTRACT
Actividad In Vitro del Benzoato de Sodio contra los Aislados de Staphylococcus aureus Resistentes a la Meticilina
O Karabay 1 , I Sahin 2 (3, 4) . Methicillin resistance and associated multiple drug resistance is a significant problem in nosocomial S aureus infection. Thus drugs that may be used against MRSA are limited and for this reason, new drugs are needed for the treatment of MRSA infections. Also known as "benzoate of soda," sodium benzoate (SB) is the sodium salt of "benzoic acid," an FDA-approved, polyunsaturated fat that has been used by food manufacturers for over 80 years to inhibit microbial growth (2) . Sodium benzoate has been used in the food industry for preserving food (ketchup, fruit juice) against almost all microorganisms. It can prevent growth of almost all micro-organisms (bacteria, yeast and moulds) (6) and has been used for the treatment of congenital metabolic diseases such as urea cycle disorders (7, 8) . We found no studies focussing on the effects of SB in MRSA infections. For this reason, in this study, the author aimed to determine the effect of SB in the MRSA isolates in vitro.
RESUMEN

Antecedentes: A nivel mundial, los índices de Staphylococcus aureus resistente a la meticilina (SARM) han aumentado dramáticamente durante las últimas décadas. El benzoato de sodio (BS) es una sustancia química que se usa ampliamente en la preparación de comidas y bebidas, y en el tratamiento de algunas enfermedades metabólicas (trastornos del ciclo de la urea y coma hepático). No encontramos ningún estudio dedicado específicamente a los efectos del BS en las infecciones por SARM. Nos trazamos como objetivo determinar la actividad in vitro
MATERIALS AND METHODS
MRSA isolates
Methicillin resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) isolates were obtained from hospitalized patients. All isolates were stored frozen in skimmed milk at -20°C and were subcultured twice onto trypticase soy agar with 5% sheep blood prior to testing. A total of 36 well-characterized clinical isolates of MRSA and 29 MSSA were selected for in vitro activity testing. Quality control for broth microdilution was performed with MRSA ATCC 33592 and MSSA ATCC 29213. The values were within the acceptable range of inhibition for these strains.
Oxacillin resistance was confirmed by broth microdilution method in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) (3). Oxacillin MICs were read at 24 hours. Quality control for broth microdilution was performed with S aureus ATCC 29213.
Susceptibly testing
Sodium benzoate was purchased commercially (Onur Kimya-Istanbul). MICs were determined by microdilution technique with an inoculum of 5 x 10 5 CFU/ml by National Committee for Clinical Laboratory standards guidelines (3). Sodium benzoate was diluted at 0.1, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512 µg/ml concentrations in cation-supplemented Mueller-Hinton broth according to NCCLS guidelines.
RESULTS
It was observed that 4/36 MRSA and 4/29 MSSA isolates were susceptible to SB at 16 µg/ml concentrations. All of the MRSA and MSSA isolates were susceptible to SB at >32 µg/ml concentrations. MRSA ATCC 33592 and MSSA ATCC 29213 isolates were found susceptible to SB at 16 µg/ml concentrations. The results are shown in the Table.   Table: In vitro activity of MRSA* and MSSA ** isolates to sodium benzoate 
MRSA (n = 36) MSSA (n = 29) SB concentrations Resistance Susceptible Resistance Susceptible
(n) (n) (n)(n)
DISCUSSION
Methicillin and multiple drug resistance is a significant problem in nosocomial as well as some community-acquired strains of S aureus (3, 10) . The drugs that have been used in the treatment of MRSA infections are restricted because of resistance and side effects. Most strains of Staphylococcus aureus are now resistant to penicillin and many MRSA strains are resistant to erythromycin, clindamycin, aminoglycoside and quinolones (11, 12) . Because a number of the drugs which have been used for the treatment of MRSA are restricted due to resistance, new drugs have been needed for the treatment of MRSA infections (13, 14) . Further new drugs are needed for the prevention and treatment of MRSA infection.
In the present study, the aim was to study in vitro activity of SB on clinically relevant MRSA isolates. In this study SB, had a good in vitro activity against all of the MRSA isolates at 32 µg/ml and higher concentrations. When the medical usage of these doses were investigated against various diseases in humans in the literature we found no study that focussed on the effects of SB on clinically relevant MRSA isolates. This chemical substance has been used in the food industry for preserving food (eg ketchup and fruit juice) against almost all micro-organisms. It has been used in long-term treatment in ornithine transcarbamylasedeficient paediatric patients and this group had previously been treated with sodium benzoate at median dose 248 mg/kg/day (15). Takeda et al (16) treated an eight-year-old girl with partial ornithine-carbamyl transferase deficiency with sodium benzoate (200 mg/kg/day) for 13 months. These investigators have not observed any adverse effect of sodium benzoate in clinical practice. These studies suggest that SB may be used in vivo at 32 µg/ml and higher concentrations.
However, Johansen and Berger (17) investigated in vitro activity of sodium benzoate on the function of polymorphonuclear leukocytes (PMN) stimulated by S aureus or the chemical agent phorbol myristate acetate (PMA), using assays of chemiluminescence, total bactericidal activity, intracellular recovery of bacteria, as well as release of lactate dehydrogenase, lysozyme and superoxide anion, in vitro. Sodium benzoate decreased chemiluminescence, superoxide anion and lysozyme release by PMN stimulated by S aureus but did not similarly affect these responses of PMN to the chemical agent PMA. The ability of PMN to kill S aureus was also impaired by sodium benzoate and associated with a reduced number of intracellular bacteria recovered after 90 minutes incubation, suggesting decreased uptake of S aureus. This is the first study investigating in vitro activities of SB on clinically relevant MRSA and MSSA isolates. Sodium benzoate seems to be a good alternative drug for the treatment of MRSA infections. We thought that, good in vitro activities of sodium benzoate suggest that, in the future, it may represent an alternative choice in the treatment of infections with antibiotic-resistant S aureus infections. Animal models might be used to evaluate SB activity in S aureus infections, as well as synergy studies to determine SB activity in combination with other antibiotics, particularly against MRSA, and studies to monitor for SB resistance development during monotherapy. It is clear that more comprehensive and in vivo studies are needed to further elucidate the activity of SB against MRSA infections.
